[procaare] Synthetic Marijuana Compound Shows Promise

[AEGIS <procaare@healthnet.org>]

Synthetic marijuana compound shows promise

Los Angeles Times - October 6, 2003
Jane E. Allen, Times Staff Writer
http://www.aegis.org/news/lt/2003/LT031002.html
****************

Marijuana can ease pain even for longtime sufferers of disease, but the illegal herb's
mind-altering properties make it less than ideal as a medication.

German researchers now have found that a synthetic version of one of many marijuana
compounds safely reduced chronic nerve pain without impairing thinking and behavior. If
the preliminary findings hold up in larger trials, capsules containing this compound might
one day be prescribed for hard-to-treat pain.

The principal active ingredient in cannabis is tetrahydrocannabinol, or THC. That compound
has been the most studied, but researchers around the world are also looking more closely
at the plant's other chemical compounds for potential health benefits. Scores of them
belong to a group called cannabinoids; others include flavonoids, which are thought to
have antioxidant properties.

"It's not a surprise that these cannabinoids have medical benefit," said Dr. Donald I.
Abrams, an AIDS specialist conducting clinical trials of marijuana at San Francisco
General Hospital.

People with cancer, AIDS and other chronic diseases have long attested to the plant's
ability to provide relief from nausea and
pain. "That's why we're investigating marijuana," Abrams said.

Previous studies have shown some cannabinoids have limited ability to blunt acute nerve
pain, typically associated with an injury. But the German study found that a cannabinoid
called CT-3 could help sufferers of chronic neuropathy, who often don't respond to
standard medications.

CT-3 is related to THC. But the problem with THC is that even at low doses, it can impair
thinking and coordination, and create anxiety, panic attacks, psychosis and paranoia, as
well as dry mouth, blurred vision, and a drop in blood pressure upon standing.

Despite these effects, scientists have remained interested in cannabinoids, because the
body has natural cannabinoid receptors that offer potential drug targets.

CT-3 first showed promise in animals as an anti-inflammatory and as a reliever of two
aspects of neuropathy: pain and extreme sensitivity to ordinary sensations.

Researchers at Hannover Medical School in Germany, working with an American colleague,
gave various doses of CT-3 to 24 volunteer patients with chronic neuropathic pain in
places such as the foot, arm, face and head. Many patients also were taking other
pain-relieving medications such as narcotics, muscle relaxants, antidepressants and
sedatives.

The researchers found that CT-3 was more effective than a placebo at relieving pain; its
effects were greatest with milder pain. Increasing the dose brought no greater relief. The
major side effects were dry mouth and fatigue.

"What's promising is that there can be a product that stimulates the cannabinoid receptors
and does not have the emotional and hallucinatory effects otherwise known for THC," said
Dr. Joel Saper, a neurologist who directs the Michigan Head-Pain and Neurological
Institute in Ann Arbor. He'd like to see longer CT-3 studies using larger numbers of
patients who aren't taking other pain medications: "We need to see how this would work in
patients not on all these drugs."

Copyright (c) 2003 - Los Angeles Times. All rights reserved.

Cross-posted from AEGIS List 07.10.03

--
ProCAARE is currently supporting the 6th Home and Community Care
Conference in Dakar, Senegal (December 8 - 12, 2003).
For more information: http://www.dakarvih2003.sn/

To send a message to ProCAARE, write to: procaare@healthnet.org
To subscribe or unsubscribe, write to: majordomo@healthnet.org
in the body of the message type: subscribe procaare OR unsubscribe procaare
To contact a person, send a message to: procaare-help@healthnet.org
Information and archives: http://www.procaare.org

The views presented in ProCAARE do not necessarily reflect the opinions of
SATELLIFE  (http://www.healthnet.org), the Harvard AIDS Institute
(http://aids.harvard.edu), or Health & Development Networks
(http://www.hdnet.org), unless otherwise stated. The reader assumes all
responsibilities in using information posted or archived by ProCAARE.
Reproduction is welcomed, provided ProCAARE and procaare@healthnet.org
are quoted, and SATELLIFE is informed of usage.